Skip to main content

Table 3 Modifiable CVD risk factor control in NOAC group at baseline and after one year FU

From: The effectiveness of atrial fibrillation special clinic on oral anticoagulant use for high risk atrial fibrillation patients managed in the community

Variables

At baseline

After 12 months

P-value§

Hypertension (n = 236)

 SBP mmHg

128.1 (± 13.3)

126.9 (± 10.9)

0.30

 DBP mmHg

71.0 (± 11.5)

68.3 (± 10.6)

0.009

  1) without DM (n = 109)

   Number of patients with satisfactory control

89 (81.7)

99 (90.8)

0.049

  2) with DM (n = 127)

   Number of patients with satisfactory control

76 (59.8)

81 (63.8)

0.52

Diabetes mellitus (n = 130)

 HbA1c %

6.68 (± 0.71)

6.65 (± 0.77)

0.71

  Number of patients with satisfactory control

89 (68.5)

97 (74.6)

0.27

Hyperlipidemia (n = 247)

 LDL-c mmol/L

1.70 (± 0.55)

1.62 (± 0.52)

0.08

  1) without history of CVD (n = 82)

   Number of patients with satisfactory control

77 (93.9)

79 (96.3)

0.72

  2) with history of CVD (n = 165)

   Number of patients with satisfactory control

109 (66.1)

125 (75.8)

0.05

  1. Data are shown as mean (± standard deviation) and number of patients (%)